According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
A number of other brokerages also recently issued reports on VTVT. ValuEngine downgraded vTv Therapeutics from a buy rating to a hold rating in a report on Monday, June 3rd. Northland Securities reiterated a buy rating and issued a $8.00 price target on shares of vTv Therapeutics in a report on Thursday, August 1st. Finally, HC Wainwright reiterated a buy rating and issued a $5.00 price target on shares of vTv Therapeutics in a report on Friday, August 16th.
Shares of NASDAQ:VTVT opened at $1.34 on Wednesday. vTv Therapeutics has a 12-month low of $0.68 and a 12-month high of $6.09. The business’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $1.67. The company has a market capitalization of $75.24 million, a PE ratio of -1.94 and a beta of -3.71.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.02. The company had revenue of $1.83 million during the quarter, compared to analysts’ expectations of $1.63 million. Sell-side analysts forecast that vTv Therapeutics will post -0.53 EPS for the current fiscal year.
In other vTv Therapeutics news, major shareholder Ronald O. Perelman bought 150,000 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were purchased at an average cost of $1.31 per share, for a total transaction of $196,500.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Ronald O. Perelman bought 1,212,121 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The shares were acquired at an average price of $1.65 per share, for a total transaction of $1,999,999.65. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 3,836,363 shares of company stock worth $6,265,499. 1.70% of the stock is owned by company insiders.
A hedge fund recently bought a new stake in vTv Therapeutics stock. Wedbush Securities Inc. purchased a new stake in shares of vTv Therapeutics Inc (NASDAQ:VTVT) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 17,500 shares of the biotechnology company’s stock, valued at approximately $30,000. 3.71% of the stock is currently owned by institutional investors.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Recommended Story: Front-End Load
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.